Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Looking for ways to earn income without a job? Discover multiple options that can help you generate extra cash on your own terms.
22,209 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A major biotech acquisition news drove a sharp move in ATAI shares. This article breaks down why ataibeckley stock so...
As the IoT market expands, Synaptics is recalibrating its business to capture devices beyond smartphones. This deep d...
L’Oréal rolls out a refreshed sustainability push that links climate goals to profits, highlighting Water Saver tech ...
Ownwell secures a $50M Series B to broaden its AI-driven tax-appeals platform and roll out a nationwide packet for ho...
A heartfelt tribute to a TV icon offers more than nostalgia. It can spark practical money moves—funeral budgeting, es...
What if you could cap downside risk while preserving upside potential? This deep dive shares how defined outcome inve...
A rising figure in Iran’s shadow government, Mojtaba Khamenei is fueling a debate over who will lead and how the econ...
The SEC is moving to settle Justin Sun's case with a $10 million penalty, a move that could reshape crypto enforcemen...
As Bitcoin prices turned volatile, Strategy—formerly MicroStrategy—pushed a high-stakes financing strategy that boost...
Oil prices rose as the IEA deployed an historic stock draw, yet Carlyle Group’s Currie argued there’s policy response...
A well-known AI stock has retraced roughly a quarter from its high, creating a potential entry point for investors. T...